

RESEARCH ARTICLE

Decrease of CD68 Synovial Macrophages in Celastrol Treated Arthritic Rats

Rita Cascão^{1*}, Bruno Vidal¹, Inês P. Lopes¹, Eunice Paisana¹, José Rino¹, Luis F. Moita^{2‡}, João E. Fonseca^{1,3‡}

1 Instituto de Medicina Molecular, Faculdade de Medicina da Universidade de Lisboa, Lisbon, Portugal, **2** Instituto Gulbenkian de Ciência, Oeiras, Portugal, **3** Rheumatology Department, Centro Hospitalar de Lisboa Norte, EPE, Hospital de Santa Maria, Lisbon Academic Medical Centre, Lisbon, Portugal

‡ LFM and JEF are joint senior authors on this work.

* ritacascascao@medicina.ulisboa.pt



Abstract

Background

Rheumatoid arthritis (RA) is a chronic immune-mediated inflammatory disease characterized by cellular infiltration into the joints, hyperproliferation of synovial cells and bone damage. Available treatments for RA only induce remission in around 30% of the patients, have important adverse effects and its use is limited by their high cost. Therefore, compounds that can control arthritis, with an acceptable safety profile and low production costs are still an unmet need. We have shown, *in vitro*, that celastrol inhibits both IL-1 β and TNF, which play an important role in RA, and, *in vivo*, that celastrol has significant anti-inflammatory properties. Our main goal in this work was to test the effect of celastrol in the number of sublining CD68 macrophages (a biomarker of therapeutic response for novel RA treatments) and on the overall synovial tissue cellularity and joint structure in the adjuvant-induced rat model of arthritis (AIA).

Methods

Celastrol was administered to AIA rats both in the early (4 days after disease induction) and late (11 days after disease induction) phases of arthritis development. The inflammatory score, ankle perimeter and body weight were evaluated during treatment period. Rats were sacrificed after 22 days of disease progression and blood, internal organs and paw samples were collected for toxicological blood parameters and serum proinflammatory cytokine quantification, as well as histopathological and immunohistochemical evaluation, respectively.

Results

Here we report that celastrol significantly decreases the number of sublining CD68 macrophages and the overall synovial inflammatory cellularity, and halted joint destruction without side effects.

OPEN ACCESS

Citation: Cascão R, Vidal B, Lopes IP, Paisana E, Rino J, Moita LF, et al. (2015) Decrease of CD68 Synovial Macrophages in Celastrol Treated Arthritic Rats. PLoS ONE 10(12): e0142448. doi:10.1371/journal.pone.0142448

Editor: Lisa F.P. Ng, Singapore Immunology Network, Agency for Science, Technology and Research (A*STAR), SINGAPORE

Received: July 30, 2015

Accepted: October 21, 2015

Published: December 11, 2015

Copyright: © 2015 Cascão et al. This is an open access article distributed under the terms of the [Creative Commons Attribution License](https://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Data Availability Statement: All relevant data are within the paper and its Supporting Information files.

Funding: RC was supported with a fellowship from Fundação para a Ciência e a Tecnologia (FCT, SFRH/BPD/92860/2013). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Competing Interests: The authors have declared that no competing interests exist.

Conclusions

Our results validate celastrol as a promising compound for the treatment of arthritis.

Introduction

Rheumatoid arthritis (RA) is a chronic immune mediated inflammatory disease that is mainly characterized by hyperproliferation of synovial cells, infiltration of mononuclear cells into the synovium and early destruction of articular cartilage and bone, causing progressive damage to the musculoskeletal system and consequently the loss of physical function and life quality [1–3]. The most debilitating feature of RA is joint destruction, which is derived from an uncontrolled inflammatory process. RA joint synovial cellular infiltrate consists of activated macrophages, B and T cells, which secrete proinflammatory cytokines and other mediators of inflammation [1, 4, 5] that not only perpetuate the inflammatory process but also increase bone resorption [6–10]. In addition, activated synovial fibroblasts, chondrocytes and osteoclasts contribute to the underlying cartilage and bone damage [11]. Despite this clear link between inflammation and increased bone turnover in RA and the existence of several therapeutic options, their efficacy on inflammation and bone treatment seem to be uncoupled, with some drugs suppressing inflammation but failing to protect bone [12, 13] and others halting bone destruction but with no effect on controlling inflammation [14]. Moreover, drugs used to treat RA, ranging from nonsteroidal anti-inflammatory drugs (NSAIDs) to disease-modifying antirheumatic drugs (DMARDs), and biological DMARDs, still cause severe side effects [15, 16] and are only able to induce remission in around 20–30% of the patients, leaving the majority of the individuals affected by RA with a chronic inflammatory process that will lead to damage. In addition to this, the most recent and innovative treatments are highly expensive, representing a burden to national health services and creating a barrier to its use in less affluent areas of the world. Therefore, compounds that can control arthritis, with an acceptable safety profile and low production cost are still an unmet need.

In this context, we have recently identified celastrol, a pentacyclic triterpenoid compound isolated from the roots of the Chinese herb *Tripterygium wilfordii* Hook F, as a potential RA therapeutic candidate [17]. We have shown that celastrol inhibits both interleukin (IL)-1 β and tumour necrosis factor (TNF), which play an important role since the early phase of RA [18], and has significant anti-inflammatory and anti-proliferative properties in an adjuvant-induced rat model of arthritis (AIA) [17]. Supporting our own results, other studies using celastrol have reported beneficial effects in various models of inflammation, diminishing joint swelling and damage, serum IgG level, TNF and IL-1 β mRNA and preventing disease progression [19]. Importantly, recent studies have also demonstrated that celastrol protects human chondrocytes by down-regulating the expression of metalloproteinases (MMPs) and inducible nitric oxide synthase (iNOS), suppresses several chemokines that mediate cellular joint infiltration [20], impairs B cell development [21] and also regulates bone remodelling-related immune mediators and proinflammatory cytokines in AIA synovium-infiltrating cells cultured *ex vivo* and in the RAW264.7 macrophagic cell line [22]. Celastrol might thus constitute an attractive candidate to have an early effect not only in controlling inflammation but also in preventing bone structural disturbances that occur in arthritis.

The efficacy of new compounds in the treatment of RA has been associated with a decrease in CD68 positive macrophages in the synovial sublining layer. This effect has been clearly demonstrated for most of the effective treatments for RA, including classic treatments, such as

prednisolone [23], gold salts [24], methotrexate [25, 26] and leflunomide [27], and also for biologics such as infliximab [28, 29], anakinra [30, 31] and rituximab [32]. Interestingly, a study of a CCL-2/MCP-1 monoclonal antibody antagonist demonstrated no change in CD68 sublining macrophages and this was associated with no change in disease activity [33]. In accordance, a C5aR antagonist did not affect CD68 sublining macrophages and no clinical effect occurred [34]. Furthermore, a multicenter study on the correlation of the number of sublining CD68 cells and the change in DAS28 demonstrated excellent inter-centre agreement [32] and it has been shown that the number of CD68 macrophages decreases with a reduction in disease activity as measured by Disease Activity Score [35]. Due to these very solid evidences, the number of CD68 sublining macrophages has been proposed as a biomarker of therapeutic response to be used in the test of novel treatments for RA [32]. Of interest, in the preclinical test of new compounds, a number of observations have shown that effective RA treatments such as tofacitinib [36] and methotrexate [37] also decrease CD68 sublining macrophages in animal models of arthritis. Several experimental compounds have also shown an association between control of arthritis and reduction in the number of CD68 macrophages in animal models of arthritis [38–40].

Our aim in the herein study was to test the effect of celastrol treatment in the number of sublining CD68 macrophages and on the overall synovial tissue cellularity and joint structure in an animal model of arthritis, as a further argument to its possible efficacy in RA treatment.

In this work we report that celastrol significantly decreases the number of sublining CD68 macrophages and the overall synovial inflammatory cellularity, and halted joint destruction without any detectable side effects.

Materials and Methods

Animal experimental design

Eight-week-old female wistar AIA rats were purchased from Charles River Laboratories International (Massachusetts, USA). AIA rats were maintained under specific pathogen free (SPF) conditions and housed per groups under standard laboratory conditions (at 22°C under 12-hour light/12-hour dark conditions). Humane end-points were established and animals were sacrificed when presenting the maximum inflammatory score in more than 2 paws or when presenting more than 20% of body weight loss. All experiments were approved by the Animal User and Ethical Committees at the Instituto de Medicina Molecular (Lisbon University), according to the Portuguese law and the European recommendations. The dose of celastrol (1µg/g body weight daily) used in this study was based on that used in our previous study [17] and in other studies [22]. The need for daily administrations is also supported by Zhang J. et al who showed that the half-life of pure celastrol is approximately 10 hours [41]. Celastrol (Sigma, Missouri, USA) stock solution of 100mg/ml in DMSO was dissolved in normal saline solution and injected intraperitoneally in AIA rats after 4 days (early treatment group) and after 11 days (late treatment group) of disease induction, when arthritis was already present. A group of healthy non-arthritic and arthritic untreated female age-matched wistar rats sacrificed at day 4 (baseline for the celastrol early-treated group, at preclinical stage, N = 13), day 11 (baseline for the celastrol late-treated group, at acute clinical stage, N = 18) and day 22 after disease induction (chronic clinical stage) were used as controls in all experiments for comparison. At the preclinical AIA progression stage evidence of inflammation or bone erosion is still lacking in the contralateral hind paw and fore paws. Hind paw swelling, inflammation and joint erosions are steadily progressing during acute clinical stage and reach a plateau in the chronic stage [42]. The inflammatory score, ankle perimeter and body weight were measured during the period of treatment. Inflammatory score was evaluated by counting the score of

each paw joint in a scale of 0–3 (0—absence; 1—erythema; 2—erythema and swelling; 3—deformities and functional impairment). The total score of each animal was defined as the sum of the partial scores of each affected joint [17, 43]. Rats were sacrificed by CO₂ narcosis and blood, internal organs as well as paw samples were collected.

Toxicological evaluation

For histopathological observation, lung, liver, kidney and spleen samples were collected at the time of sacrifice. Samples were fixed immediately in 10% neutral buffered formalin solution and then dehydrated with increasing ethanol concentrations (70%, 96% and 100%). Samples were next embedded in paraffin, sectioned using a microtome, mounted on microscope slides and stained with hematoxylin and eosin. Tissue histopathological changes were examined by a pathologist blinded to the experimental groups. All images were acquired using a Leica DM 2500 microscope equipped with a color camera Leica MC170 HD (Leica microsystems, Wetzlar, Germany). Moreover, blood toxicological parameters, such as creatine kinase, urea, lactate dehydrogenase and alanine transaminase, were measured in serum samples by enzyme linked immunosorbent assay (ELISA) technique according to the manufacturer's instructions (BioAssay Systems, California, USA). Samples were analyzed using a plate reader Infinite M200 (Tecan, Mannedorf, Switzerland).

Systemic cytokine quantification

Proinflammatory cytokines IL-1 β (Boster Bio, California, USA), IL-6 (Boster Bio, California, USA), IL-17 (Sunred Biological Technology, Shanghai, China) and TNF (RayBiotech, Georgia, USA) were quantified in serum samples using specific rat ELISA kits according to the provider's recommendations. Standard curves for each cytokine were generated by using reference cytokine concentrations supplied by the manufacturer. Samples were analyzed using a plate reader Infinite M200 (Tecan, Mannedorf, Switzerland).

Histological and immunohistochemical evaluation of hind paws

Left hind paw samples collected at the time of sacrifice were fixed immediately in 10% neutral buffered formalin solution and then decalcified in 10% formic acid. Samples were next dehydrated and embedded in paraffin, serially sectioned at a thickness of 5 μ m using a microtome, mounted on microscope slides and stained with hematoxylin and eosin for morphological examination of structural changes and cellular infiltration. Histopathological evaluation of rat joints was performed in a blind fashion using 4 semi-quantitative scores: Sublining layer infiltration score (0—none to diffuse infiltration; 1—lymphoid cell aggregate; 2—lymphoid follicles; 3—lymphoid follicles with germinal center formation); Lining layer cell number score (0—fewer than three layers; 1—three to four layers; 2—five to six layers; 3—more than six layers); Bone erosion score (0—no erosions; 1—minimal; 2—mild; 3—moderate; 4—marked); Global severity score (0—no signs of inflammation; 1—mild; 2—moderate; 3—severe) [17, 44, 45]. Paw sections were also used for immunohistochemical staining with CD68 (Abcam, Cambridge, UK), CD163 (Biorbyt, Massachusetts, USA), CD3 (Abcam, Cambridge, UK), CD19 (Biorbyt, Massachusetts, USA) and Ki67 (Abcam, Cambridge, UK) antibodies. Tissue sections were incubated with the primary antibody and with EnVision+ (Dako, Glostrup, Denmark). Color was developed in solution containing diaminobenzadine-tetrahydrochloride (Sigma, Missouri, USA), 0.5% H₂O₂ in phosphate-buffered saline buffer (pH 7.6). Slides were counter-stained with hematoxylin and mounted. Immunohistochemical evaluation of rat joints was performed in a blind fashion using a semi-quantitative score of 0–4 (0—no staining; 1–0–25% staining; 2–25–50% staining; 3–50–75% staining; 4—more than 75% staining) [17]. Images

were acquired using a Leica DM2500 (Leica Microsystems, Wetzlar, Germany) microscope equipped with a color camera.

For a quantitative analysis of the immunohistochemical staining, we acquired whole-slide color images of single tissue slides using a NanoZoomer SQ slide scanner (Hamamatsu Photonics, Hamamatsu City, Japan) with 20x magnification (0.46 μm resolution). We developed an image analysis software written in MATLAB (Mathworks, Natick, MA) to identify and count the number of positive cells that displayed a specific cytoplasmic staining in representative sections. Briefly, single cell nuclei stained with hematoxylin were identified by color thresholding in the $L^*a^*b^*$ color space with the range of parameters $L^* = [40,72]$, $a^* = [-11,20]$ and $b^* = [-37,12]$ followed by particle analysis. Dilated regions of interest (ROIs) with a radius of 5 pixels were next defined for each detected particle as the cytoplasmic area. The antibody staining was also identified by color thresholding in the $L^*a^*b^*$ color space with the range of parameters $L^* = [40,80]$, $a^* = [-6,20]$ and $b^* = [-0.2,33]$. Each cell ROI was then evaluated for antibody positive staining, defined by the occurrence of at least 20 pixels with a color value included in the cytoplasmic $L^*a^*b^*$ threshold range. We cropped areas of interest from whole-slide color images corresponding to synovial membranes and the software was set to batch process all images and output the total number of cells and the number of cells with positive antibody staining for each section. Then the density of positive cells was calculated by dividing the positive cell count by the area value.

Statistical analysis

Statistical differences were determined with non-parametric Kruskal-Wallis (Dunn's Multiple Comparison tests) and Mann-Whitney tests using GraphPad Prism (GraphPad, California, USA). Correlation analysis was performed with the Spearman test. Differences were considered statistically significant for $p < 0.05$.

Results

Celastrol safely suppresses inflammatory manifestations in rat adjuvant-induced arthritis

To further validate the *in vivo* anti-inflammatory effect of celastrol in the context of arthritis, we have used the AIA rat model. The AIA experimental arthritis shares some characteristics of RA, such as hyperplasia of the synovial membrane, inflammatory infiltration of the joints, deposition of immune complexes in articular cartilage, pannus formation and destruction of bone. This model is also useful to characterize treatment responses by the reduction of inflammation or changes in the synovial tissue [46]. Overall, the AIA model has been extensively used to clarify the mechanisms of human RA pathogenesis and to identify potential targets and new drugs for therapeutic intervention [47], and has thus been our model of choice for our first experimental use of celastrol [17, 48].

Celastrol was intraperitoneally administered at a dose of 1 $\mu\text{g/g}$ /daily after 4 days of disease induction (early treatment group) and after 11 days of disease induction (late treatment group) [17]. The inflammatory score and ankle perimeter were evaluated during the treatment period (Fig 1 and S1 Fig). As shown in Fig 1A, all animals already presented signs of arthritis by the fourth day of disease induction and after 9 days the untreated arthritic group started to increase the inflammatory manifestations sharply. In contrast, in early celastrol-treated rats there was minimal inflammatory activity or even complete abrogation of arthritis manifestations. In the late treatment group, drug administration was started when animals already presented a mean inflammatory score of 4, but celastrol still caused a significant decrease of arthritis manifestations




Fig 1. (A) Celastrol ameliorates inflammation throughout time. Notice that after 7 days of treatment celastrol early-treated rats presented minimal inflammatory activity, whereas arthritic rats started to increase the inflammatory manifestations sharply. Arrows indicate the beginning of treatment after 4 and 11 days of disease induction. (B) Celastrol improves the clinical outcome in adjuvant-induced arthritic rats. Inflammatory score in celastrol-treated AIA rats is maintained significantly diminished in comparison with arthritic rats. (C) Celastrol suppresses the progression of swelling in the left hind paw. Left paw edema/swelling is markedly present in arthritic rats in contrast to celastrol-treated animals. Data are expressed as median with interquartile range. Differences were considered statistically significant for p -values < 0.05 , according to the Kruskal-Wallis (Dunn's Multiple Comparison tests) and Mann-Whitney tests. Healthy $N = 19$, Arthritic $N = 23$, Celastrol early group $N = 15$ and Celastrol late group $N = 15$.

doi:10.1371/journal.pone.0142448.g001

over time. In fact, the only remaining sign of swelling was observed in most animals in the local of injection of the adjuvant, for disease induction. This result shows that this drug has a significant anti-inflammatory effect even when administrated at a later phase of arthritis development. Celastrol showed a significant anti-inflammatory effect, as assessed by the evaluation of the inflammatory score ($p < 0.0001$ in early and late treatment groups vs. arthritic animals, shown in Fig 1B) and also by the measurement of ankle perimeter ($p < 0.0001$ in early and late treatment groups vs. arthritic animals, shown in Fig 1C). Of note, by the end of the treatment, at day 22, there were no significant differences between the celastrol early and late treatment groups. Importantly, both treated groups showed a significant reduction in the inflammatory score when compared with their baselines ($p = 0.0002$ in celastrol early-treated vs. arthritic rats sacrificed at day 4 and $p < 0.0001$ in celastrol-late treated vs. arthritic rats sacrificed at day 11).

Up to now significant adverse effects of celastrol administration have not been reported. However the few toxicological analysis of this compound *in vivo* were based in data from the assessment of animal mortality and some blood parameters in studies using *Tripterygium wilfordii* plant extracts [49]. To investigate the potential side effects of pure celastrol

administration in AIA rats, we performed liver and renal function tests, such as the measurement of creatine kinase, urea, lactate dehydrogenase and alanine transaminase in serum samples collected at the time of sacrifice. No significant differences were observed in these parameters when comparing arthritic rats with animals under treatment ($p = 0.2$). In addition, a pathologist blinded to experimental groups examined the tissue histological sections and has reported no evidence of drug-induced liver or renal injury, as well as no lung or spleen alterations (S2 Fig). Of note, body weight variations were recorded throughout treatment duration, and no weight loss was observed due to celastrol administration ($p = 0.1265$ and $p = 0.6005$ in celastrol early and late treatment groups vs. arthritic rats, respectively). Contrarily, there was an association between disease activity and weight loss ($p = 0.0273$ in arthritic rats vs. healthy animals). In fact, in the late treatment group, animals started to lose weight due to disease activity and after treatment was initiated no more weight loss was observed ($p = 0.0436$ in late-treated rats at day 11 vs. day 4, and $p = 0.9009$ in late-treated rats at day 22 vs. day 11) (S3 Fig). Importantly, administration of celastrol has already been tested in healthy animals in a wide range of concentrations [21]. So far, there are no data showing deleterious effects at a dose of 1mg/kg (the concentration used in this work).

Celastrol diminishes systemic proinflammatory cytokine IL-6 *in vivo*

Proinflammatory cytokines, namely IL-1 β , IL-6, IL-17 and TNF act synergistically to maintain inflammation and bone erosions in animal models of arthritis and in RA patients. These cytokines activate the NF- κ B pathway that in turn leads to the downstream up-regulation of several cytokines, chemokines and MMPs, which are responsible for the inflammatory process and for the destruction of cartilage and bone. We therefore aimed at evaluating the anti-inflammatory effect of celastrol on the peripheral circulating levels of these cytokines. We have observed that IL-6 levels increase in the serum of AIA rats throughout the course of arthritis, although abundant production was seen only after 2 weeks of disease onset. Thus, IL-6, which is produced by monocytes/macrophages, T cells and synovial fibroblasts [50], seems to be involved in the systemic events underlying arthritis, especially in the transition phase of its development. Fig 2 shows that celastrol administration significantly reduces the levels of IL-6 detected in peripheral blood, both in early and late treatment groups ($p < 0.0001$ in both groups vs. arthritic rats




Fig 2. Celastrol reduces the serum levels of IL-6 in arthritic rats. Notice that celastrol treatment significantly reduces the systemic concentration of the proinflammatory cytokine IL-6 to levels similar to healthy controls. Data are expressed as median with interquartile range. Differences were considered statistically significant for p -values < 0.05 , according to the Kruskal-Wallis (Dunn's Multiple Comparison tests) and Mann-Whitney tests. Healthy $N = 21$, Arthritic $N = 23$, Celastrol early group $N = 15$ and Celastrol late group $N = 15$.

doi:10.1371/journal.pone.0142448.g002

after 22 days of disease induction), presenting a cytokine concentration similar to healthy controls. Importantly, both treated groups showed a significant reduction in the circulating levels of IL-6 when compared with their baselines ($p = 0.0387$ in celastrol early-treated vs. arthritic rats sacrificed at day 4 and $p < 0.0001$ in celastrol-late treated vs. arthritic rats sacrificed at day 11). This observation is corroborated by data already published which shows that IL-6 mRNA is decreased after celastrol treatment *in vitro* [51]. We have also quantified the circulating concentration of IL-1 β , IL-17 and TNF, but no differences were found when comparing arthritic rats with animals under celastrol treatment or with healthy controls ($p > 0.05$, S4 Fig), possibly because these cytokines are not increased in the periphery at this stage of disease development. Previously, we have demonstrated that circulating IL-1 β and IL-17 are only increased in the early phase of RA, in contrast to IL-6, which was found to be increased also in the later phase of the disease [18], arguing that the detection of these cytokines in the periphery is dependent on disease evolution. In addition, literature controversy highlights the likelihood that systemic markers and mediators of arthritis might not fully reflect the underlying local disease progression. AIA rat model have increased levels of IL-1 β (since the preclinical disease stage), IL-6, IL-17 and TNF (in the acute and chronic stages) locally in the joints [42]. Recently, it has been shown in the same animal model that both Tripterygium and celastrol decrease the levels of these cytokines locally in the arthritic joints [19, 20, 22, 52].

Celastrol ameliorates local joint inflammation and bone damage in AIA rats

To evaluate the effect of celastrol in the preservation of local articular joint synovium and bone structures, paw sections stained with hematoxylin and eosin were performed (illustrative images can be observed in Fig 3). The histological evaluation using 4 semi-quantitative scores is depicted in Fig 4.

The levels of the sublining layer infiltration (Fig 4A) and the lining layer cell numbers (Fig 4B) started to augment immediately after 4 days of disease onset and continued to markedly increase until the end of the study ($p < 0.0001$, healthy vs. arthritic rats sacrificed after 22 days of disease induction). The data from Fig 4D revealed that rats treated with celastrol had a normal joint structure at the end of the study period, with an abrogation of the inflammatory infiltrate and a reduction of the number of cells present in the lining layer of the synovial membrane ($p < 0.0001$ in early and late treatment groups vs. arthritic animals). Moreover, when comparing the infiltration score of celastrol early-treated group with diseased animals at baseline (day 4), we observed that there was a complete clearance of the cellular infiltrate ($p = 0.0006$ in the early-treated group sacrificed at the end of the treatment period vs. arthritic rats sacrificed at baseline of the treatment period, i.e. after 4 days of disease induction), with a phenotype similar to a healthy control. Regarding the analysis of the lining layer cell number score (Fig 4B), data showed that both celastrol early and late treatment groups have dramatically reduced scores, in comparison with the animals at the beginning of treatment, corresponding to baseline ($p = 0.0107$ in early-treated arthritic rats sacrificed at the end of the study period vs. arthritic rats sacrificed at baseline, at day 4 and $p < 0.0001$ in late-treated arthritic rats sacrificed at the end of the study period vs. arthritic rats sacrificed at baseline, at day 11, respectively).

Celastrol is also effective in preventing bone articular destruction as shown in Fig 4C. The development of bone erosions in the AIA rat model occurred immediately after 4 days of disease onset, and markedly increased throughout the development of arthritis ($p < 0.0001$ in healthy vs. arthritic rats sacrificed after 22 days of disease induction), with a strong correlation between erosion and infiltration as well as with proliferation scores ($r^2 = 0.70$, $p = 0.0009$ and




Fig 3. Histological images of joints after celastrol treatment. These patterns are merely illustrative of the type of histological features observed. Black arrow indicates the absence/presence of ankle swelling in rat hind paws. C—calcaneus, E—edema or erosion, S—synovia, Tb—tibia, Ts—tarso. Magnification of 50x. Bar: 100 μ m.

doi:10.1371/journal.pone.0142448.g003

$r^2 = 0.97$, $p < 0.0001$, respectively). By the end of the treatment course, celastrol was able to suppress the appearance of bone erosions ($p < 0.0001$ in both celastrol early and late treatment groups vs. arthritic rats), maintaining the phenotype similar to their baselines. These results might suggest that celastrol is able to modulate osteoclast pathways. In fact, a study has demonstrated that celastrol inhibits the formation and activity of mature osteoclasts, induces their apoptosis and reduces osteoblast viability and activity *in vitro* [53].

Overall, these data are supported by studies already published in the literature using several plant extracts and different experimental outlines [19, 20, 22, 54, 55]. Thus, there is strong




Fig 4. Celastrol suppresses arthritic inflammation and tissue damage locally in the joints of AIA rats. A semi-quantitative evaluation of histological sections was performed. Notice that celastrol has inhibited cellular infiltration (A), completely reversed the number of lining layer cells to the normal values (B) and prevented bone erosion occurrence (C), allowing for a normal joint structure comparable to healthy rats in both early and late treatment groups (D). Data are expressed as median with interquartile range. Differences were considered statistically significant for p -values < 0.05 , according to the Kruskal-Wallis (Dunn's Multiple Comparison tests) and Mann-Whitney tests. Correlation analysis was performed using the Spearman test. Healthy $N = 19$, Arthritic $N = 23$, Celastrol early group $N = 15$ and Celastrol late group $N = 15$.

doi:10.1371/journal.pone.0142448.g004

evidence that celastrol is able to significantly diminish inflammation and bone damage, even when administrated in a later phase of arthritis development.

Celastrol inhibits synovial lymphocyte infiltration and cell proliferation in arthritic rat joints

The immunohistochemical analysis revealed that arthritic rats treated with celastrol have reduced levels of lymphocyte infiltration into the joints (Fig 5). As can be observed in Fig 5B there were significant reductions of CD3+ T cells ($p < 0.0001$ in early and late treatment groups vs. arthritic rats) and CD19+ B cells ($p < 0.0001$ in early and late treatment groups vs. arthritic rats). In contrast, the number of these cells markedly increased throughout disease progression in untreated animals ($p < 0.0001$ in healthy vs. arthritic rats, sacrificed at the end of the study period). A study by Venkatesha et al, have shown that celastrol reduces the level of chemokines, which might explain the inhibition of leukocyte migration [20].

In addition, we have also studied cell proliferation by staining joint tissue sections with the Ki67 marker. The immunohistochemical results shown in Fig 5B revealed that animals treated with celastrol have reduced levels of synovial cell proliferation in both early and late treated rats ($p < 0.0001$ in both groups vs. arthritic animals), with a score similar to the healthy controls.

Results of immunohistochemical quantification also showed that celastrol significantly reduced CD3+ T cells ($p = 0.0079$ in both early and late treatment groups vs. arthritic rats) and CD19+ B cells ($p = 0.0317$ in both early and late treatment groups vs. arthritic rats) infiltrated into the joints as well as synovial cell proliferation ($p = 0.0079$ in both early and late treatment groups vs. arthritic rats), as depicted in Fig 5C.




Fig 5. Celastrol reduces the number of T cells and B cells present in the synovial membrane, and suppresses synovial cell proliferation. (A) Representation of the immunohistochemical evaluation performed in paw sections at day 22 after celastrol treatment. Magnifications of 200x. Bar: 100 μ m. (B) Immunohistochemical analysis was performed using a semi-quantitative score. Notice that both celastrol early and late-treated rats showed a significant reduction in the number of CD3 and CD19 positive cells as well as a reduction in the levels of synovial cell proliferation assessed by Ki67 marker in comparison with arthritic rats at day 22. Healthy N = 16, Arthritic N = 10, Celastrol early group N = 15 and Celastrol late group N = 15. (C) Immunohistochemical quantification was performed using an image analysis software written in MATLAB to identify and count the number of positive cells for each antibody in representative sections. Notice that both celastrol early and late-treated rats showed a significant reduction in the number of CD3, CD19 and Ki67 positive cells in comparison with arthritic rats at day 22. Healthy N = 5, Arthritic N = 5, Celastrol early group N = 5 and Celastrol late group N = 5. Data are expressed as median with interquartile range. Differences were considered statistically significant for p-values < 0.05, according to the Kruskal-Wallis (Dunn's Multiple Comparison tests) and Mann-Whitney tests.

doi:10.1371/journal.pone.0142448.g005

Celastrol significantly reduces CD68+ macrophages in the arthritic synovial tissue

The activated macrophages in the synovium are derived from circulating monocytes and secrete various mediators that participate in arthritis induction and tissue injury. Studies of drug efficacy in RA patients have identified, from a large panel of synovial biomarkers, sublining CD68+ macrophages as an optimal marker to evaluate clinical response, with an association between clinical improvement and the reduction of CD68+ macrophage scores. Therefore, CD68+ sublining macrophages have been recognized as a synovial biomarker, with a high sensitivity in discriminating between effective and ineffective therapies or placebo, useful in an early stage of drug development [34, 56]. We have thus performed the characterization of CD68+ macrophages present in the synovial tissue after treatment with celastrol (Fig 6). Arthritic rats have shown an increase in the number of CD68+ synovial macrophages throughout the development of the disease ($p < 0.0001$ in healthy vs. arthritic rats, as shown in Fig 6B). Importantly, celastrol significantly decreased the number of CD68+ macrophages infiltrated into the arthritic joint tissue ($p < 0.0001$ in early and late treatment groups vs. arthritic rats). In addition, celastrol administration significantly decreased the levels of CD163+ macrophages ($p < 0.0001$ in early and late treatment groups vs. arthritic rats). CD163 is a useful marker in




Fig 6. Celastrol reduces the number of synovial CD68+ macrophages. (A) Representation of the immunohistochemical evaluation performed in paw sections at day 22 after celastrol treatment. Magnifications of 200x. Bar: 100 μ m. (B) Immunohistochemical analysis was performed using a semi-quantitative score. Notice that both celastrol early and late-treated rats showed a significant reduction in the number of CD68 and CD163 positive cells in comparison with arthritic rats at day 22. Healthy N = 16, Arthritic N = 10, Celastrol early group N = 15 and Celastrol late group N = 15. (C) Immunohistochemical quantification was performed using an image analysis software written in MATLAB to identify and count the number of positive cells for each antibody in representative sections. Notice that both celastrol early and late-treated rats showed a significant reduction in the number of CD68 and CD163 positive cells in comparison with arthritic rats at day 22. Healthy N = 5, Arthritic N = 5, Celastrol early group N = 5 and Celastrol late group N = 5. Data are expressed as median with interquartile range. Differences were considered statistically significant for p-values < 0.05, according to the Kruskal-Wallis (Dunn’s Multiple Comparison tests) and Mann-Whitney tests.

doi:10.1371/journal.pone.0142448.g006

this context because it is a more selective macrophage marker and helps to discriminate between synovial macrophages and synovial intimal fibroblasts, which also stain positively for CD68 in RA synovium [57]. Previous studies have in fact shown that synovial intimal fibroblasts migration and invasion into the synovium are also reduced by celastrol [55, 58].

Results of immunohistochemical quantification shown in Fig 6C also revealed that celastrol significantly reduced CD68+ cells ($p = 0.0079$ in both early and late treatment groups vs. arthritic rats) and CD163+ macrophages ($p = 0.0079$ in both early and late treatment groups vs. arthritic rats) infiltrated into the joints.

Because inflammatory synovial tissue macrophages are derived from peripheral blood monocytes, these observations suggest decreased monocyte recruitment into the joints of arthritic rats treated with celastrol, even when treatment was initiated in a later phase of disease development.

Discussion

In this study, we have shown that celastrol substantially depletes CD68+ sublining synovial cells, considered to be the biomarker with the strongest association with response to treatment in RA. Moreover, celastrol was effective and safe in suppressing synovial inflammation and bone damage in rats with AIA.

We have consistently observed that celastrol treatment reduced serum IL-6 levels in arthritic rats. This observation is relevant because IL-6 is a proinflammatory cytokine that plays a relevant role in the pathogenesis of RA, namely in Th17 polarization and plasma B cell differentiation, in the production of chemokines, adhesion molecules, and VEGF, and in the secretion of RANKL and MMPs, amplifying inflammatory cell infiltration and inducing osteoclastogenesis [59–61]. Interestingly, it was shown that celastrol can suppress arthritis in part by altering Th17/Treg ratio in inflamed joints [52]. Additionally, celastrol-treated rats showed a significant

reduction in the severity of clinical arthritis as well as in pannus formation and leukocyte cell infiltration into the joint synovial tissue. This cell infiltration and proliferation inhibitory effect of celastrol may thus prove to be of interest to prevent and treat the development of the synovial tumor-like pannus tissue characteristic of established RA and responsible for bone damage. Interestingly, histological analysis also revealed that celastrol is effective in suppressing local inflammation-induced bone loss. Of note, celastrol treatment is effective when administered both in the early and established phase of arthritis, which is relevant for the potential clinical implications of our findings. Our report is the first to demonstrate the protective coupled effect of celastrol *in vivo* on both synovial inflammation and joint bone damage restoring synovial homeostasis, fulfilling this unmet medical need in RA treatment approach. Importantly, CD68 + sublining macrophages, a synovial biomarker with a high sensitivity in selecting effective RA therapies in an early stage of drug development, is significantly reduced in the synovia of celastrol-treated rats.

It has already been reported that celastrol targets NF- κ B, via long-lasting inhibition of IKK β activity [62]. In fact, the inactivation of NF- κ B in animal models has shown the ability to suppress arthritis [63]. NF- κ B participates in the transcription of genes encoding many proinflammatory cytokines and chemokines, in the regulation of different immune cells and in the expression of adhesion molecules and matrix MMPs [64]. Based on microarray gene expression profile it has been demonstrated that celastrol represses cell proliferation, inflammation and immune responses (targets T and B cells, antigen processing and presentation), blocks metabolic pathways, has anti-oxidant properties, and targets VEGF, proinflammatory cytokines and chemokines [65]. Indeed, it has been demonstrated that celastrol reduces the levels of chemokines, possibly affecting leukocyte migration [20]. Celastrol has thus a broad spectrum of targets, modulating immune responses rather than inducing immunosuppression [65]. Our results point out that pure celastrol used in the AIA rat model is not associated with increased risk of infections, have no hepatotoxicity or nephrotoxicity, suggesting that at least for short-term RA treatment, celastrol might be a safe drug.

Overall, our results validate celastrol as a promising compound for the treatment of inflammation and inflammation-induced bone damage and provide relevant insights into the usage of celastrol as a future drug for RA. It would be interesting to extend this knowledge by studying the anti-arthritic properties of celastrol *in vivo* using different animal models of arthritis, namely the CIA model, and evaluate differences in efficacy depending on animal gender.

Supporting Information

S1 Fig. Ankle perimeter kinetics. Celastrol was administered to AIA rats both in the early (4 days after disease induction) and late (11 days after disease induction) phases of arthritis development. Notice that after 7 days of treatment celastrol early-treated rats presented an ankle perimeter similar to the healthy control, whereas arthritic rats started to increase left ankle edema/swelling sharply. In the celastrol late-treated group, ankle swelling started to increase in parallel to the augment of the inflammatory score, but after treatment was initiated ankle perimeter started to significantly decrease. Data are expressed as median with interquartile range. Differences were considered statistically significant for p-values < 0.05, according to the Kruskal-Wallis (Dunn's Multiple Comparison tests) and Mann-Whitney tests. Healthy N = 19, Arthritic N = 23, Celastrol early group N = 15 and Celastrol late group N = 15. (TIF)

S2 Fig. Administration of pure celastrol induces no hepatic or renal toxicity. At day 22 after disease induction no hepatocellular or renal lesion was observed in any of the animals. Liver and kidney samples from all animals were analyzed by a pathologist blinded to experimental

groups but only representative histological sections are shown. H&E staining; Magnifications of 100×. Bar: 300 μm.

(TIF)

S3 Fig. Celestrol treatment has no effect on body weight. Notice that no weight loss was observed due to celestrol administration. In contrast, there was an association between disease activity and weight loss, which was highlighted in late-treated rats that started to lose weight due to disease activity (day 4 up to day 11) and after treatment was initiated no more weight loss was observed (day 11 up to day 22). Data are expressed as median with interquartile range. Differences were considered statistically significant for p-values < 0.05, according to the Mann-Whitney tests.

(TIF)

S4 Fig. Celestrol has no effect in the serum levels of IL-1β, IL-17 and TNF in arthritic rats. Data are expressed as median with interquartile range. Differences were considered statistically significant for p-values < 0.05, according to the Kruskal-Wallis (Dunn's Multiple Comparison tests) and Mann-Whitney tests. Healthy N = 19, Arthritic N = 23, Celestrol early group N = 15 and Celestrol late group N = 15.

(TIF)

Acknowledgments

The authors would like to acknowledge Ana Lopes, the Histology and Comparative Pathology Laboratory and the Bioimaging Facility from Instituto de Medicina Molecular for technical assistance.

Author Contributions

Conceived and designed the experiments: RC LFM JEF. Performed the experiments: RC BV IPL EP JR. Analyzed the data: RC BV IPL EP. Contributed reagents/materials/analysis tools: JR JEF. Wrote the paper: RC LFM JEF.

References

1. Gorman CL, Cope AP. Immune-mediated pathways in chronic inflammatory arthritis. *Best practice & research Clinical rheumatology*. 2008; 22(2):221–38.
2. Hahn B. A pathophysiologic approach to the clinical management of arthritis and pain: current and future implications. *Journal of clinical rheumatology: practical reports on rheumatic & musculoskeletal diseases*. 2004; 10(3 Suppl):S3–4.
3. Plasqui G. The role of physical activity in rheumatoid arthritis. *Physiology & behavior*. 2008; 94(2):270–5.
4. Steiner G, Tohidast-Akrad M, Witzmann G, Vesely M, Studnicka-Benke A, Gal A, et al. Cytokine production by synovial T cells in rheumatoid arthritis. *Rheumatology*. 1999; 38(3):202–13. PMID: [10325658](#)
5. Astry B, Harberts E, Moudgil KD. A cytokine-centric view of the pathogenesis and treatment of autoimmune arthritis. *Journal of interferon & cytokine research: the official journal of the International Society for Interferon and Cytokine Research*. 2011; 31(12):927–40.
6. Boyce BF, Xing L. Functions of RANKL/RANK/OPG in bone modeling and remodeling. *Archives of biochemistry and biophysics*. 2008; 473(2):139–46. doi: [10.1016/j.abb.2008.03.018](#) PMID: [18395508](#)
7. Karmakar S, Kay J, Gravallese EM. Bone damage in rheumatoid arthritis: mechanistic insights and approaches to prevention. *Rheumatic diseases clinics of North America*. 2010; 36(2):385–404. doi: [10.1016/j.rdc.2010.03.003](#) PMID: [20510240](#)
8. Kotake S, Udagawa N, Takahashi N, Matsuzaki K, Itoh K, Ishiyama S, et al. IL-17 in synovial fluids from patients with rheumatoid arthritis is a potent stimulator of osteoclastogenesis. *The Journal of clinical investigation*. 1999; 103(9):1345–52. PMID: [10225978](#)

9. Schett G. Rheumatoid arthritis: inflammation and bone loss. *Wiener medizinische Wochenschrift*. 2006; 156(1–2):34–41. PMID: [16465612](#)
10. Xu S, Wang Y, Lu J, Xu J. Osteoprotegerin and RANKL in the pathogenesis of rheumatoid arthritis-induced osteoporosis. *Rheumatology international*. 2012; 32(11):3397–403. doi: [10.1007/s00296-011-2175-5](#) PMID: [22057136](#)
11. Gravallesse EM, Manning C, Tsay A, Naito A, Pan C, Amento E, et al. Synovial tissue in rheumatoid arthritis is a source of osteoclast differentiation factor. *Arthritis and rheumatism*. 2000; 43(2):250–8. PMID: [10693863](#)
12. Fonseca JE, Canhao H, Tavares NJ, Cruz M, Branco J, Queiroz MV. Persistent low grade synovitis without erosive progression in magnetic resonance imaging of rheumatoid arthritis patients treated with infliximab over 1 year. *Clinical rheumatology*. 2009; 28(10):1213–6. doi: [10.1007/s10067-009-1207-y](#) PMID: [19504146](#)
13. Joosten LA, Helsen MM, Saxne T, van De Loo FA, Heinegard D, van Den Berg WB. IL-1 alpha beta blockade prevents cartilage and bone destruction in murine type II collagen-induced arthritis, whereas TNF-alpha blockade only ameliorates joint inflammation. *Journal of immunology*. 1999; 163(9):5049–55.
14. Smolen JS, Han C, Bala M, Maini RN, Kalden JR, van der Heijde D, et al. Evidence of radiographic benefit of treatment with infliximab plus methotrexate in rheumatoid arthritis patients who had no clinical improvement: a detailed subanalysis of data from the anti-tumor necrosis factor trial in rheumatoid arthritis with concomitant therapy study. *Arthritis and rheumatism*. 2005; 52(4):1020–30. PMID: [15818697](#)
15. Singh JA, Furst DE, Bharat A, Curtis JR, Kavanaugh AF, Kremer JM, et al. 2012 update of the 2008 American College of Rheumatology recommendations for the use of disease-modifying antirheumatic drugs and biologic agents in the treatment of rheumatoid arthritis. *Arthritis care & research*. 2012; 64(5):625–39.
16. Vivar N, Van Vollenhoven RF. Advances in the treatment of rheumatoid arthritis. *F1000prime reports*. 2014; 6:31. doi: [10.12703/P6-31](#) PMID: [24860653](#)
17. Cascao R, Vidal B, Raquel H, Neves-Costa A, Figueiredo N, Gupta V, et al. Effective treatment of rat adjuvant-induced arthritis by celastrol. *Autoimmunity reviews*. 2012; 11(12):856–62. doi: [10.1016/j.autrev.2012.02.022](#) PMID: [22415021](#)
18. Cascao R, Moura RA, Perpetuo I, Canhao H, Vieira-Sousa E, Mourao AF, et al. Identification of a cytokine network sustaining neutrophil and Th17 activation in untreated early rheumatoid arthritis. *Arthritis research & therapy*. 2010; 12(5):R196.
19. Li H, Zhang YY, Tan HW, Jia YF, Li D. Therapeutic effect of tripterine on adjuvant arthritis in rats. *Journal of ethnopharmacology*. 2008; 118(3):479–84. doi: [10.1016/j.jep.2008.05.028](#) PMID: [18577440](#)
20. Venkatesha SH, Astry B, Nanjundaiah SM, Yu H, Moudgil KD. Suppression of autoimmune arthritis by *Celastrus*-derived Celastrol through modulation of pro-inflammatory chemokines. *Bioorganic & medicinal chemistry*. 2012; 20(17):5229–34.
21. Kusy S, Ghosn EE, Herzenberg LA, Contag CH. Development of B cells and erythrocytes is specifically impaired by the drug celastrol in mice. *PloS one*. 2012; 7(4):e35733. doi: [10.1371/journal.pone.0035733](#) PMID: [22545133](#)
22. Nanjundaiah SM, Venkatesha SH, Yu H, Tong L, Stains JP, Moudgil KD. *Celastrus* and its bioactive celastrol protect against bone damage in autoimmune arthritis by modulating osteoimmune cross-talk. *The Journal of biological chemistry*. 2012; 287(26):22216–26. doi: [10.1074/jbc.M112.356816](#) PMID: [22549786](#)
23. Gerlag DM, Haringman JJ, Smeets TJ, Zwinderman AH, Kraan MC, Laud PJ, et al. Effects of oral prednisolone on biomarkers in synovial tissue and clinical improvement in rheumatoid arthritis. *Arthritis and rheumatism*. 2004; 50(12):3783–91. PMID: [15593225](#)
24. Yanni G, Nabil M, Farahat MR, Poston RN, Panayi GS. Intramuscular gold decreases cytokine expression and macrophage numbers in the rheumatoid synovial membrane. *Annals of the rheumatic diseases*. 1994; 53(5):315–22. PMID: [8017985](#)
25. Smith MD, Kraan MC, Slavotinek J, Au V, Weedon H, Parker A, et al. Treatment-induced remission in rheumatoid arthritis patients is characterized by a reduction in macrophage content of synovial biopsies. *Rheumatology*. 2001; 40(4):367–74. PMID: [11312372](#)
26. Dolhain RJ, Tak PP, Dijkmans BA, De Kuiper P, Breedveld FC, Miltenburg AM. Methotrexate reduces inflammatory cell numbers, expression of monokines and of adhesion molecules in synovial tissue of patients with rheumatoid arthritis. *British journal of rheumatology*. 1998; 37(5):502–8. PMID: [9651076](#)
27. Kraan MC, Reece RJ, Barg EC, Smeets TJ, Farnell J, Rosenberg R, et al. Modulation of inflammation and metalloproteinase expression in synovial tissue by leflunomide and methotrexate in patients with active rheumatoid arthritis. Findings in a prospective, randomized, double-blind, parallel-design clinical

- trial in thirty-nine patients at two centers. *Arthritis and rheumatism*. 2000; 43(8):1820–30. PMID: [10943872](#)
28. Smeets TJ, Kraan MC, van Loon ME, Tak PP. Tumor necrosis factor alpha blockade reduces the synovial cell infiltrate early after initiation of treatment, but apparently not by induction of apoptosis in synovial tissue. *Arthritis and rheumatism*. 2003; 48(8):2155–62. PMID: [12905468](#)
 29. Taylor PC, Peters AM, Paleolog E, Chapman PT, Elliott MJ, McCloskey R, et al. Reduction of chemokine levels and leukocyte traffic to joints by tumor necrosis factor alpha blockade in patients with rheumatoid arthritis. *Arthritis and rheumatism*. 2000; 43(1):38–47. PMID: [10643698](#)
 30. Thurlings RM, Vos K, Wijbrandts CA, Zwinderman AH, Gerlag DM, Tak PP. Synovial tissue response to rituximab: mechanism of action and identification of biomarkers of response. *Annals of the rheumatic diseases*. 2008; 67(7):917–25. PMID: [17965121](#)
 31. Cunnane G, Madigan A, Murphy E, FitzGerald O, Bresnihan B. The effects of treatment with interleukin-1 receptor antagonist on the inflamed synovial membrane in rheumatoid arthritis. *Rheumatology*. 2001; 40(1):62–9. PMID: [11157143](#)
 32. Bresnihan B, Pontifex E, Thurlings RM, Vinkenoog M, El-Gabalawy H, Fearon U, et al. Synovial tissue sublining CD68 expression is a biomarker of therapeutic response in rheumatoid arthritis clinical trials: consistency across centers. *The Journal of rheumatology*. 2009; 36(8):1800–2. doi: [10.3899/jrheum.090348](#) PMID: [19671815](#)
 33. Haringman JJ, Gerlag DM, Smeets TJ, Baeten D, van den Bosch F, Bresnihan B, et al. A randomized controlled trial with an anti-CCL2 (anti-monocyte chemotactic protein 1) monoclonal antibody in patients with rheumatoid arthritis. *Arthritis and rheumatism*. 2006; 54(8):2387–92. PMID: [16869001](#)
 34. Wijbrandts CA, Vergunst CE, Haringman JJ, Gerlag DM, Smeets TJ, Tak PP. Absence of changes in the number of synovial sublining macrophages after ineffective treatment for rheumatoid arthritis: Implications for use of synovial sublining macrophages as a biomarker. *Arthritis and rheumatism*. 2007; 56(11):3869–71. PMID: [17968928](#)
 35. Haringman JJ, Gerlag DM, Zwinderman AH, Smeets TJ, Kraan MC, Baeten D, et al. Synovial tissue macrophages: a sensitive biomarker for response to treatment in patients with rheumatoid arthritis. *Annals of the rheumatic diseases*. 2005; 64(6):834–8. PMID: [15576415](#)
 36. LaBranche TP, Jesson MI, Radi ZA, Storer CE, Guzova JA, Bonar SL, et al. JAK inhibition with tofacitinib suppresses arthritic joint structural damage through decreased RANKL production. *Arthritis and rheumatism*. 2012; 64(11):3531–42. doi: [10.1002/art.34649](#) PMID: [22899318](#)
 37. Kim HY, Lee SW, Park SY, Baek SH, Lee CW, Hong KW, et al. Efficacy of concurrent administration of cilostazol and methotrexate in rheumatoid arthritis: pharmacologic and clinical significance. *Life sciences*. 2012; 91(7–8):250–7. doi: [10.1016/j.lfs.2012.07.003](#) PMID: [22820172](#)
 38. Ma Y, Wang X, Wu X, Wei X, Ma L, Zheng H, et al. (Z)-5-(4-methoxybenzylidene) thiazolidine-2, 4-dione ameliorates the adjuvant-induced arthritis via inhibiting the migration of macrophage and down-regulating the cytokine mRNA expression. *International immunopharmacology*. 2010; 10(11):1456–62. doi: [10.1016/j.intimp.2010.08.022](#) PMID: [20837171](#)
 39. Chen SY, Wu CL, Lai MD, Lin CC, Yo YT, Jou IM, et al. Amelioration of rat collagen-induced arthritis through CD4+ T cells apoptosis and synovial interleukin-17 reduction by indoleamine 2,3-dioxygenase gene therapy. *Human gene therapy*. 2011; 22(2):145–54. doi: [10.1089/hum.2009.217](#) PMID: [20825285](#)
 40. Le Goff B, Soltner E, Charrier C, Maugars Y, Redini F, Heymann D, et al. A combination of methotrexate and zoledronic acid prevents bone erosions and systemic bone mass loss in collagen induced arthritis. *Arthritis research & therapy*. 2009; 11(6):R185.
 41. Zhang J, Li CY, Xu MJ, Wu T, Chu JH, Liu SJ, et al. Oral bioavailability and gender-related pharmacokinetics of celastrol following administration of pure celastrol and its related tablets in rats. *Journal of ethnopharmacology*. 2012; 144(1):195–200. doi: [10.1016/j.jep.2012.09.005](#) PMID: [22982018](#)
 42. Stolina M, Bolon B, Middleton S, Dwyer D, Brown H, Duryea D, et al. The evolving systemic and local biomarker milieu at different stages of disease progression in rat adjuvant-induced arthritis. *J Clin Immunol*. 2009; 29(2):158–74. doi: [10.1007/s10875-008-9238-8](#) PMID: [18726678](#)
 43. da Silva JA, Fonseca JE, Graca L, Moita L, Carmo-Fonseca M. Reinnervation of post-arthritis joints in the rat. *Clinical and experimental rheumatology*. 1996; 14(1):43–51. PMID: [8697656](#)
 44. Tsubaki T, Arita N, Kawakami T, Shiratsuchi T, Yamamoto H, Takubo N, et al. Characterization of histopathology and gene-expression profiles of synovitis in early rheumatoid arthritis using targeted biopsy specimens. *Arthritis research & therapy*. 2005; 7(4):R825–36.
 45. Sims NA, Green JR, Glatt M, Schlicht S, Martin TJ, Gillespie MT, et al. Targeting osteoclasts with zoledronic acid prevents bone destruction in collagen-induced arthritis. *Arthritis and rheumatism*. 2004; 50(7):2338–46. PMID: [15248235](#)

46. Brauer R, Kittlick PD, Thoss K, Henzgen S. Different immunological mechanisms contribute to cartilage destruction in antigen-induced arthritis. *Experimental and toxicologic pathology: official journal of the Gesellschaft fur Toxikologische Pathologie*. 1994; 46(4–5):383–8.
47. Bendele AM, Chlipala ES, Scherrer J, Frazier J, Sennello G, Rich WJ, et al. Combination benefit of treatment with the cytokine inhibitors interleukin-1 receptor antagonist and PEGylated soluble tumor necrosis factor receptor type I in animal models of rheumatoid arthritis. *Arthritis and rheumatism*. 2000; 43(12):2648–59. PMID: [11145022](#)
48. Vidal B, Cascao R, Vale AC, Cavaleiro I, Vaz MF, Brito JA, et al. Arthritis induces early bone high turnover, structural degradation and mechanical weakness. *PloS one*. 2015; 10(1):e01117100. doi: [10.1371/journal.pone.01117100](#) PMID: [25617902](#)
49. Zhu X, Zhang J, Huo R, Lin J, Zhou Z, Sun Y, et al. Evaluation of the efficacy and safety of different Tripterygium preparations on collagen-induced arthritis in rats. *Journal of ethnopharmacology*. 2014; 158 Pt A:283–90. doi: [10.1016/j.jep.2014.10.021](#) PMID: [25456434](#)
50. Nawroth PP, Bank I, Handley D, Cassimeris J, Chess L, Stern D. Tumor necrosis factor/cachectin interacts with endothelial cell receptors to induce release of interleukin 1. *The Journal of experimental medicine*. 1986; 163(6):1363–75. PMID: [3011946](#)
51. Venkatesha SH, Yu H, Rajaiah R, Tong L, Moudgil KD. Celastrol-derived celastrol suppresses autoimmune arthritis by modulating antigen-induced cellular and humoral effector responses. *The Journal of biological chemistry*. 2011; 286(17):15138–46. doi: [10.1074/jbc.M111.226365](#) PMID: [21402700](#)
52. Astry B, Venkatesha SH, Laurence A, Christensen-Quick A, Garzino-Demo A, Frieman MB, et al. Celastrol, a Chinese herbal compound, controls autoimmune inflammation by altering the balance of pathogenic and regulatory T cells in the target organ. *Clinical immunology*. 2015; 157(2):228–38. doi: [10.1016/j.clim.2015.01.011](#) PMID: [25660987](#)
53. Idris AI, Krishnan M, Simic P, Landao-Bassonga E, Mollat P, Vukicevic S, et al. Small molecule inhibitors of I κ B kinase signaling inhibit osteoclast formation in vitro and prevent ovariectomy-induced bone loss in vivo. *FASEB journal: official publication of the Federation of American Societies for Experimental Biology*. 2010; 24(11):4545–55.
54. Gan K, Xu L, Feng X, Zhang Q, Wang F, Zhang M, et al. Celastrol attenuates bone erosion in collagen-Induced arthritis mice and inhibits osteoclast differentiation and function in RANKL-induced RAW264.7. *International immunopharmacology*. 2015; 24(2):239–46. doi: [10.1016/j.intimp.2014.12.012](#) PMID: [25529994](#)
55. Li G, Liu D, Zhang Y, Qian Y, Zhang H, Guo S, et al. Celastrol inhibits lipopolysaccharide-stimulated rheumatoid fibroblast-like synoviocyte invasion through suppression of TLR4/NF- κ B-mediated matrix metalloproteinase-9 expression. *PloS one*. 2013; 8(7):e68905. doi: [10.1371/journal.pone.0068905](#) PMID: [23861949](#)
56. Vieira-Sousa E, Gerlag DM, Tak PP. Synovial tissue response to treatment in rheumatoid arthritis. *The open rheumatology journal*. 2011; 5:115–22. doi: [10.2174/1874312901105010115](#) PMID: [22279510](#)
57. Fonseca JE, Edwards JC, Blades S, Goulding NJ. Macrophage subpopulations in rheumatoid synovium: reduced CD163 expression in CD4+ T lymphocyte-rich microenvironments. *Arthritis and rheumatism*. 2002; 46(5):1210–6. PMID: [12115225](#)
58. Li GQ, Zhang Y, Liu D, Qian YY, Zhang H, Guo SY, et al. Celastrol inhibits interleukin-17A-stimulated rheumatoid fibroblast-like synoviocyte migration and invasion through suppression of NF- κ B-mediated matrix metalloproteinase-9 expression. *International immunopharmacology*. 2012; 14(4):422–31. doi: [10.1016/j.intimp.2012.08.016](#) PMID: [22954486](#)
59. Suzuki M, Hashizume M, Yoshida H, Shiina M, Mihara M. IL-6 and IL-1 synergistically enhanced the production of MMPs from synovial cells by up-regulating IL-6 production and IL-1 receptor I expression. *Cytokine*. 2010; 51(2):178–83. doi: [10.1016/j.cyto.2010.03.017](#) PMID: [20403707](#)
60. Mihara M, Moriya Y, Kishimoto T, Ohsugi Y. Interleukin-6 (IL-6) induces the proliferation of synovial fibroblastic cells in the presence of soluble IL-6 receptor. *British journal of rheumatology*. 1995; 34(4):321–5. PMID: [7788145](#)
61. Romano M, Sironi M, Toniatti C, Polentarutti N, Fruscella P, Ghezzi P, et al. Role of IL-6 and its soluble receptor in induction of chemokines and leukocyte recruitment. *Immunity*. 1997; 6(3):315–25. PMID: [9075932](#)
62. Lee JH, Koo TH, Yoon H, Jung HS, Jin HZ, Lee K, et al. Inhibition of NF- κ B activation through targeting I κ B kinase by celastrol, a quinone methide triterpenoid. *Biochemical pharmacology*. 2006; 72(10):1311–21. PMID: [16984800](#)
63. Tas SW, Vervoordeldonk MJ, Hajji N, May MJ, Ghosh S, Tak PP. Local treatment with the selective I κ B kinase beta inhibitor NEMO-binding domain peptide ameliorates synovial inflammation. *Arthritis research & therapy*. 2006; 8(4):R86.

64. Vincenti MP, Coon CI, Brinckerhoff CE. Nuclear factor kappaB/p50 activates an element in the distal matrix metalloproteinase 1 promoter in interleukin-1beta-stimulated synovial fibroblasts. *Arthritis and rheumatism*. 1998; 41(11):1987–94. PMID: [9811054](#)
65. Yu H, Venkatesha SH, Moudgil KD. Microarray-based gene expression profiling reveals the mediators and pathways involved in the anti-arthritic activity of Celastrus-derived Celastrol. *International immunopharmacology*. 2012; 13(4):499–506. doi: [10.1016/j.intimp.2012.05.015](#) PMID: [22664142](#)